Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribupatide in Participants Living With Obesity
NCT07458269Phase 2Active, not recruiting
- Sponsor
- Kailera Therapeutics
- Start
- Mar 2026
- Primary completion
- May 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of ribupatide in obesity, sponsored by Kailera Therapeutics. Started Mar 2026; status: active, not recruiting.
02
Drugs
ribupatide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07458269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07458269.